EC Number   |
Inhibitors |
Structure |
|---|
    4.1.1.45 | 1,3-dihydroxyacetonephosphate |
- |
   |
| 4.1.1.45 | 2-hydroxymuconate 6-semialdehyde |
- |
|
| 4.1.1.45 | 3-[[[5-cyano-1,6-dihydro-6-oxo-4-(2-thienyl)-2-pyrimidinyl]thio]methyl]phenylacetic acid |
potent and selective inhibitor. Treatment of primary hepatocytes significantly increases intracellular NAD+ levels. compound exhibits good solubility with low permeability of cells and no inhibition of cytochrome P450s |
|
| 4.1.1.45 | Cd2+ |
0.5 mM, reduces the enzymatic activity to 25% |
|
| 4.1.1.45 | Cr3+ |
0.5 mM, reduces the enzymatic activity to 35% |
|
| 4.1.1.45 | CuSO4 |
- |
|
| 4.1.1.45 | diethyldicarbonate |
- |
|
| 4.1.1.45 | EDTA |
- |
|
| 4.1.1.45 | eicosapentaenoic acid |
ACMSD mRNA levels in primary hepatocytes are decreased by the incubation with high concentrations of eicosapentaenoic acid |
|
| 4.1.1.45 | Fe3+ |
0.1 mM, reduces the enzymatic activity to 15% |
|
